RENAL SYSTEM: Edited by Marlies OstermannNew drugs for acute kidney injuryCôté, Jean-Maximea,b,c; Murray, Patrick T.a,b; Rosner, Mitchell H.dAuthor Information aClinical Research Centre, University College Dublin bSchool of Medicine, University College Dublin, Dublin, Ireland cDivision of Nephrology, Department of Medicine, Montreal University Health Centre, Montreal, Quebec, Canada dDivision of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA Correspondence to Patrick T. Murray, University College Dublin, Catherine McAuley Centre, Nelson Street, Dublin 7, Ireland. Tel: +353 1 7164531; e-mail: [email protected] Current Opinion in Critical Care: December 2020 - Volume 26 - Issue 6 - p 525-535 doi: 10.1097/MCC.0000000000000778 Buy Metrics Abstract Purpose of review To describe recent advances in the development of therapeutic agents for acute kidney injury (AKI). Recent findings Traditional care for AKI is mostly supportive. At present, no specific therapy has been developed to prevent or treat AKI. However, based on a better understanding of the pathophysiology of AKI, various potential compounds have been recently identified and tested. A variety of pathways has been targeted, including oxidative and mitochondrial stress, cellular metabolism and repair, inflammation, apoptosis and hemodynamics. Many of these potential agents are currently ongoing early-phase clinical trials, and the purpose of this review is to provide a summary of those with the most potential. Summary Despite the lack of therapies specifically approved for AKI, many interesting potential agents are entering clinical trials, with the potential to transform the care of patients with AKI. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.